SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- mBC

ecancer

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- mBC

By ecancer FEATURING Virginia Kaklamani

2,419 views

January 10, 2023

This video was recorded prior to FDA approval of ORSERDU™ (elacestrant) on January 27, 2023 ...
read more ↘

Comments 2

Login

Login

Join VuMedi

ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- mBC

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

SABCS 2022 Genomic Assay and Prediction of Long-Term Prognosis in Pr…

SABCS 2022 Breast Cancer Patients and Interrupted ET to Pursue Pregn…

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

SABCS 2022 Primary Results From the POSITIVE Trial: Interruption of …

SABCS 2022 Follow-Up of Patients With Early BC After 30 Years: Radio…

SABCS 2022 Phase 3 DESTINY-Breast02 Study: T-DXd Efficacy in Patient…

SABCS 2022 Treatment Decision Guided by CTC Count and Long-Term Outc…

SABCS 2022 Updates From TAILORx and RxPONDER Trials: Implications fo…